Researchers from the University of Bergen, Norway, have found a new method that within hours can predict if certain cancer patients will survive or not after chemotherapy.
Acute myeloid leukaemia is an aggressive blood cancer with poor survival. Although high rates of initial chemotherapy response, patients often relapse due to the selection and development of chemotherapy-resistant leukaemic cells.
"When treating patients with leukaemia, it is challenging to quickly follow if the patient is responding to therapy or not says Benedicte Sjo Tislevoll", researcher at the University of Bergen and leader of the new study.
The response to therapy is currently measured after weeks to months of treatment, thereby losing important time. However, an immediate response to chemotherapy can be measured by investigating the functional properties of the leukaemic cells.
"Our results show that the protein ERK1/2 increases within the first 24 hours of chemotherapy in patients who have a poor response to therapy. We believe that this protein is responsible for the cancer cells’ resistance to chemotherapy and can be used to distinguish responders from non-responders", the researcher says.
"We think that this is an important key in our understanding of cancer, and our aim is to use this information to change treatment early for patients who are not responding to therapy", Tislevoll concludes.
Source: The University of Bergen
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.